Clinical Trial Update: Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nivolumab with oral cyclophosphamide for relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome has complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Higher-risk Myelodysplastic Syndrome

Drugs mentioned

• nivolumab (nivolumab)
• oral cyclophosphamide (cyclophosphamide)

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Acute Myeloid Leukemia, Higher Risk Myelodysplastic Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2023-05-26